Abstract Introduction One standard of care for advanced non-small cell lung cancer (NSCLC) is paclitaxel plus carboplatin±bevacizumab. This two-step phase I study evaluated the feasibility of adding everolimus to paclitaxel plus carboplatin±bevacizumab for advanced NSCLC. Methods Adults with advanced NSCLC naive to systemic therapy were enrolled. A Bayesian dose-escalation model was used to identify feasible daily or weekly everolimus doses given with paclitaxel (200 mg/m 2 q21 days) and carboplatin (AUC 6 mg/mL/min q21 days) (step 1) and paclitaxel (200 mg/m 2 q21 days), carboplatin (AUC 6 mg/mL/min q21 days), and bevacizumab (15 mg/kg q21 days) (step 2). Primary endpoint was end-of-cycle 1 dose-limiting toxicity (DLT) rate. Secondary endpoints included safety; relative dose intensities of paclitaxel, carboplatin, and bevacizumab; pharmacokinetics; and tumor response. Results Fifty-two patients were enrolled and received everolimus 5 mg/day plus carboplatin and paclitaxel (step 1 daily; n=13); everolimus 30 mg/week plus carboplatin and paclitaxel (step 1 weekly; n=13); everolimus 5 mg/day plus carboplatin, paclitaxel, and bevacizumab (step 2 daily; n=13); or everolimus 30 mg/week plus carboplatin, paclitaxel, and bevacizumab (step 2 weekly; n=13). End-ofcycle 1 DLT rate was 16.7 % (step 1 daily), 30.8 % (step 1 weekly), 30.0 % (step 2 daily), and 16.7 % (step 2 weekly). Cycle 1 DLTs were grade 3 neutropenia, anal abscess, diarrhea, and thrombocytopenia and grade 4 myalgia, cellulitis, neutropenia, febrile neutropenia, pulmonary embolism, and thrombocytopenia. The most common adverse events were
Introduction
In patients with stage IIIB/IV non-small cell lung cancer (NSCLC), platinum-based chemotherapy prolongs survival and improves symptom control when given with thirdgeneration cytotoxic agents [1] . Accumulating evidence suggests that even newer platinum-based combinations including gemcitabine, vinorelbine, paclitaxel, and docetaxel, as well as pemetrexed for non-squamous cell carcinoma, have reached a plateau in their attainable overall response and efficacy, with 1-year survival rates of approximately 30 %-40 % [1] [2] [3] . Thus, despite recent advances in chemotherapy, including new strategies to deliver prolonged cytostatic administration via switch or continuation maintenance treatment with pemetrexed in selected patients and development of molecularly targeted agents, the prognosis for advanced NSCLC continues to be poor, with a median survival of ≤12 months in unselected patients [2, 3] .
Based on current knowledge of cellular pathways in lung cancer, several new targets are being pursued. One is the mammalian target of rapamycin (mTOR), a signal transduction molecule implicated in cancer development and progression [4] . Everolimus is an oral mTOR inhibitor that has shown antitumor activity in in vitro and in vivo tumor models [5] [6] [7] , including NSCLC cell lines [5, [8] [9] [10] . Everolimus is currently approved in various countries for treating hormone receptor-positive, HER2-negative advanced breast cancer in combination with exemestane after failure of anastrozole or letrozole; sorafenib-or sunitinib-refractory advanced renal cell carcinoma; progressive; unresectable, locally advanced or metastatic pancreatic neuroendocrine tumors; subependymal giant cell astrocytomas not amenable to surgery in patients with tuberous sclerosis; and renal angiomyolipoma not requiring immediate surgery in patients with tuberous sclerosis [11] [12] [13] [14] .
Everolimus monotherapy has demonstrated modest clinical activity in pretreated advanced NSCLC [15] . However, preclinical data suggest adding everolimus to cytotoxics may provide improved activity [5, 16] . In one study, everolimus sensitized human NSCLC cells to cisplatininduced apoptosis, thereby demonstrating the potential to enhance the cisplatin therapeutic window [5] . In another study, everolimus demonstrated synergy with cisplatin and moderate synergy with paclitaxel [16] . NSCLC xenograft studies demonstrated dose-dependent synergy between everolimus and cisplatin and synergy between everolimus and low-dose paclitaxel [16] . Clinical evidence for benefit of adding everolimus to cytotoxic chemotherapy in NSCLC comes from a phase I study of everolimus plus docetaxel for advanced NSCLC that progressed following ≥1 chemotherapy regimen [15] .
Carboplatin plus paclitaxel±bevacizumab confers significant survival benefits in advanced NSCLC [17] and has become one of the standards of care for advanced NSCLC. Here, we report results of a 2-step, phase I study designed to assess the feasibility of administering everolimus with carboplatin and paclitaxel (step 1) or carboplatin, paclitaxel, and bevacizumab (step 2) in patients with advanced, metastatic NSCLC not previously treated with systemic anticancer therapy (ClinicalTrials.gov unique identifier NCT00457119).
Methods

Patients
Eligible patients were aged ≥18 years with histologically or cytologically proven advanced NSCLC (stage IIIB/IV UICC/IASLC-6 disease) [18] previously untreated with systemic therapy for advanced disease (systemic therapy for operable disease [eg, adjuvant chemotherapy or combination chemoradiotherapy] was permitted). Other key eligibility criteria included World Health Organization (WHO) performance status ≤1 and adequate bone marrow, hepatic, and renal function. Key exclusion criteria included severe and/or uncontrolled medical conditions, wide-field radiation therapy to ≥25 % of bone marrow within 4 weeks of study entry, limited radiation therapy for palliation within 2 weeks before first study treatment, previous therapy with everolimus or other mTOR inhibitors, or known sensitivity to carboplatin (or other platinum derivatives), paclitaxel (or other taxanes), or bevacizumab. Patients with squamous cell histology, brain metastasis, history of thrombotic or hemorrhagic disorders, gross hemoptysis, or an international normalized ratio >1.5 and a partial thromboplastin time above the upper limit of normal within 1 week prior to study treatment were excluded from step 2.
Study design
This open-label, multicenter, two-step, phase I study was designed using a Bayesian sequential dose-escalation scheme based on a time-to-event model of the doselimiting toxicity (DLT) rate, which estimates the probability that a patient will experience a DLT within their first treatment cycle (ie, end-of-cycle 1 DLT rate). Adverse events (AEs) meeting the definition of a DLT are summarized in Table 1 . A time-to-event model was selected to ensure prompt response to the occurrence of any DLT during the first treatment cycle. The model used all DLTs occurring within a given regimen irrespective of when they occurred. This design allowed flexibility regarding the number of patients enrolled at each dose level, avoiding the need for predefined cohort sizes.
The model was regularly updated to allow decision making about the next dose level to consider. Decision-making time points occurred after every DLT occurring within cycle 1, after the first 6 patients in a schedule completed cycle 1 or had documented discontinuation due to a DLT during cycle 1, and, in the absence of the first two criteria, every 2 months thereafter. At each time point, the next dose level chosen was that which maximized the probability of the end-of-cycle 1 DLT rate falling within the targeted toxicity interval [20 %-35 %], had a <5 % probability of the end-of-cycle 1 DLT rate falling within unacceptable toxicity interval [60 %-100 %] and a <25 % probability of it falling within the excessive [35 %-60 %] or unacceptable [60 %-100 %] toxicity intervals combined.
The study was conducted according to the Declaration of Helsinki ethical principles. The study protocol was reviewed by independent ethics committees or institutional review boards for each participating center. Written informed consent was obtained from each patient before study enrollment.
Study treatment
The study was conducted in two successive steps. In step 1, patients received intravenous paclitaxel (200 mg/m 2 over 3 h) followed 60 min later by intravenous carboplatin (area under the curve of 6 mg/mL/min over 30 min) on day 1 of a 21-day cycle. In step 2, intravenous bevacizumab (15 mg/kg over 90 min) was given 60 min after carboplatin. During both steps, everolimus was administered orally on daily (days 1-21) or weekly (days 1, 8, and 15) schedules. In cycle 1, everolimus dosing began on day 2 to permit serial blood sampling for pharmacokinetic evaluation of carboplatin and paclitaxel in the absence of everolimus. The starting everolimus doses were 5 mg/day and 30 mg/week. Within each step and schedule, up to two additional dose levels were planned: 2.5 and 10 mg/day and 20 and 50 mg/week. Per clinical guidelines [19, 20] , all patients received standard supportive antiemetic therapy.
Patients in steps 1 and 2 who completed the core treatment phase (ie, the first 6 treatment cycles) or who discontinued chemotherapy early entered the extension phase. During this phase, maintenance treatment with everolimus (patients from step 1) or everolimus plus bevacizumab (patients from step 2) was continued until disease progression, unacceptable toxicity, or consent withdrawal.
Study objectives
The primary study objective was to establish the feasible everolimus doses/regimens given with carboplatin and paclitaxel (step 1) or carboplatin, paclitaxel, and bevacizumab (step 2) based on an evaluation of safety during the core treatment phase. Secondary objectives included determining the carboplatin, paclitaxel, and bevacizumab relative dose intensities (RDIs); assessing the influence of carboplatin and paclitaxel on everolimus pharmacokinetics; and determining best overall tumor response according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0 [21] .
Safety assessments included continuous AE collection; weekly hematology monitoring; and physical examination and assessment of vital signs, body weight, blood chemistry, urinalysis, and electrocardiograms (step 2 only) every 3 weeks. AEs were assessed according to the Common Terminology Criteria for Adverse Events, version 3.0. Blood samples for pharmacokinetic assessment of daily everolimus were collected predose and 0.5, 1, 2, 4, and 24 h postdose on day 8 of cycle 1 and day 1 of cycle 2; samples for weekly everolimus were collected predose and 0.5, 1, 2, 4, 24, and 168 h postdose. Additional predose samples were collected during cycles 3 through 6. Blood samples for carboplatin and paclitaxel pharmacokinetic assessment were collected 24 h after paclitaxel was administered on day 1 of cycle 1 (ie, without everolimus) and predose and 24 h after paclitaxel was administered on day 1 of cycle 2 (ie, with everolimus). At each time point, 2 mL venous blood was collected into a tube containing sodium heparin or EDTA. Everolimus samples were frozen at or below −20°C until shipment. Everolimus concentrations in whole blood were determined by a liquid chromatography-mass spectrometry method (lower limit of quantification [LLOQ], 0.3 ng/mL). Carboplatin and paclitaxel samples were centrifuged at 3°C-5°C for 10 min at~1,500 g; plasma was transferred to polypropylene tubes and stored at or below −80°C until analysis. Carboplatin and paclitaxel concentrations were measured using validated liquid chromatography-tandem mass spectrometry methods (LLOQ, 0.1 μg/mL and 1 ng/mL, respectively). Everolimus pharmacokinetic parameters of maximum concentration (C max ), time to reach C max (t max ), trough concentration (C min ), area under the curve from time 0 to last measurable concentration (AUC 0-last ), and AUC in the dosing interval (AUC tau ) were derived by noncompartmental analysis using WinNonlin Version 5.2 (Pharsight, Mountain View, CA, USA).
Tumor measurements were assessed using chest and upper abdomen computed tomography (CT) scans performed at baseline and repeated after cycles 2, 4, and 6 during the core phase and every 6-8 weeks during the extension. Brain magnetic resonance imaging or CT was performed at baseline in step 2 only. Complete or partial responses according to RECIST required confirmation using the same assessment method ≥4 weeks after initial response observation.
Statistical analysis
No formal sample size calculation was performed. It was anticipated that approximately 30 patients would be sufficient to complete dose escalation within a given regimen and ensure the desired confidence level in the end-of-cycle 1 DLT rate and carboplatin, paclitaxel, and bevacizumab (step 2 only) RDIs would be reached.
The full analysis set included all patients who received ≥1 dose of any study treatment. The safety population included all patients who received ≥1 dose of any study treatment and had ≥1 postbaseline safety assessment. The dose-determining population included all patients from the safety population who met the minimum exposure requirement (≤7 daily or ≤1 weekly everolimus dose missed and paclitaxel and bevacizumab RDIs of ≥95 % and carboplatin RDI ≥80 % in cycle 1) or who experienced a DLT at any time during the core phase. The pharmacokinetic population included all patients in the safety population who had eligible trough samples and pharmacokinetic parameters.
Results
Patients
Of 70 patients screened, 52 were enrolled between March 2007 and March 2009, with 26 patients each allocated to steps 1 and 2; in each step, 13 received daily and 13 received weekly everolimus (Fig. 1) . Of 52 patients enrolled, 15 completed the core treatment phase and 14 entered the extension phase. AEs were the most common reason for discontinuation during the core phase (n=20).
In the total study population, 61.5 % of patients were aged <65 years, 48.1 % were women, 86.5 % had stage IV disease, 80.8 % were current or former smokers, and 63.5 % had a WHO performance status of 1 ( Table 2 ). Within steps 1 and 2, baseline demographics were broadly comparable across treatment schedules. Imbalances were noted between steps 1 and 2. In step 1, the majority of patients were men (57.7 %), whereas women were the majority in step 2 (53.8 %). More patients in step 2 were aged <65 years (69.2 % vs 53.8 % in step 1).
Dose-limiting toxicities
In the dose-determining population (n=47), the percentage of patients who experienced a DLT during any cycle was 68.0 % for step 1 and 81.8 % for step 2 (Table 3) . Cycle 1 DLTs were observed in 2 (16.7 %) and 4 (30.8 %) patients in the step 1 daily and weekly schedules, respectively. In step 2, cycle 1 DLTs were observed in 3 (30.0 %) and 2 (16.7 %) patients in the daily and weekly schedules, respectively. Neutropenia was the most common DLT, with the highest incidence in the step 2 daily schedule. The other DLTs were bacterial sepsis, dehydration, fatigue, febrile neutropenia, lower respiratory tract infection, peripheral neuropathy, thrombocytopenia, and urosepsis in the step 1 daily schedule; cellulitis, febrile neutropenia, hypophosphatemia, myalgia, pulmonary embolism, pneumonia, pneumonitis, and thrombocytopenia in the step 1 weekly schedule; anal abscess, colitis, diarrhea, febrile neutropenia, gastroenteritis, hypokalemia, and increased aspartate aminotransferase in the step 2 daily schedule; and colitis, fatigue, peripheral neuropathy, pneumothorax, and thrombocytopenia in the step 2 weekly schedule.
After four decision-making points in step 1, with 13 patients enrolled in each treatment schedule, everolimus 5 mg/day and 30 mg/week were declared the feasible doses.
Based on these outcomes, step 1 enrollment was considered complete and step 2 enrollment was initiated at everolimus 5 mg/day and 30 mg/week. After two decision-making points, with 7 patients enrolled in each schedule, the Bayesian model suggested escalating everolimus to 10 mg/day and 50 mg/week. However, everolimus dosing was not increased due to toxicity concerns (increased DLTs in later cycles and hematologic toxicity), and recruitment continued at 5 mg/day and 30 mg/week until 13 patients were enrolled in each schedule. End-of-cycle 1 DLT posterior probability rates based on the Bayesian model are summarized in Table 3 .
Adverse events
All patients reported ≥1 AE (Table 4) . Neutropenia was the most frequently reported AE and occurred at similar rates in all treatment arms (84.6 % in the daily schedules of steps 1 and 2 and 76.9 % in the weekly schedules of steps 1 and 2). Additional AEs reported in >50 % of patients in either arm of step 1 were anemia, leukopenia, thrombocytopenia, fatigue, and alopecia and in step 2, fatigue, nausea, epistaxis, thrombocytopenia, anemia, and alopecia. Most patients (90.4 %) also experienced grade 3/4 AEs, most frequently neutropenia (73.1 %) and leukopenia (42.3 %) ( Table 4 ). Incidence of grade 3/4 AEs was generally similar across treatment arms. Serious AEs were experienced by 55.8 % (Table 4) . Noninfectious pneumonitis of grade ≥3 was not identified as a major nonhematologic toxicity in any schedule or step. No deaths were reported during study treatment or within 28 days thereafter.
Overall, more patients in step 2 experienced AEs leading to treatment discontinuation (53.8 % vs 34.6 % in step 1), with the highest incidence observed in the step 2 weekly schedule (69.2 %) ( Table 4 ). AEs that led to treatment discontinuation in ≥2 patients were peripheral neuropathy (n=5) and neutropenia and thrombocytopenia (n=2 each).
Exposure and relative dose intensity
In step 1, median duration of exposure to combination therapy was 13.43 weeks in the daily schedule and 9.29 weeks in the weekly schedule (Table 5 ). In step 2, median duration of exposure was similar (16.43 and 13.29 weeks in the daily and weekly schedules, respectively). Among the eight patients entering the step 1 extension phase, median duration of everolimus exposure was 7 weeks. In step 2, four patients entered the extension and received everolimus and bevacizumab; an additional two patients received everolimus alone. Among these patients, median duration of exposure was 18 weeks. In step 1, the carboplatin and paclitaxel RDIs were similar in the daily and weekly schedules (Table 5 ). In step 2, the carboplatin, paclitaxel, and bevacizumab RDIs were higher in the weekly than the daily schedule ( Table 5 ). Regardless of step or schedule, the majority of patients had an RDI that fell within the 0.70 to <1.10 range (data not shown).
Pharmacokinetics
In the step 1 daily schedule, everolimus AUC 0-last , AUC tau , and C max estimates suggested a trend towards a greater than dose-proportional increase when everolimus was administered with carboplatin and paclitaxel (Table 6 ). In the step 2 daily schedule, everolimus AUC 0-last and AUC tau estimates suggested a less than dose-proportional increase when everolimus was administered with carboplatin, paclitaxel, and bevacizumab, whereas a greater than dose-proportional increase for C max was suggested (Table 6 ). For both steps, the 90 % confidence intervals associated with beta were wide and crossed unity, suggesting a large variability in model estimates. Similar results were obtained for steps 1 and 2 of the weekly everolimus schedule (data not shown).
Carboplatin plus paclitaxel did not influence the AUC 0-last , AUC tau , or C max of daily or weekly everolimus in step 1 (data not shown). In step 2, minor decreases in everolimus AUC 0-last , Table 2 Patient demographics, baseline characteristics and disease history (full analysis set)
Step 1
Step 2 AUC tau , and C max were noted in the daily schedule when everolimus was given with carboplatin, paclitaxel, and bevacizumab compared with being given alone; in the weekly schedule, the carboplatin/paclitaxel/bevacizumab combination did not appear to influence these parameters (data not shown).
Efficacy
The most frequent best overall response across treatment arms was stable disease (Table 7) . One patient in step 2 treated with the daily schedule achieved complete response. Two patients in each daily schedule and three patients in each weekly schedule achieved partial response. Objective response rates (percentage of patients with complete or partial response) were 15.4 % for the step 1 daily schedule and 23.1 % for the remaining 3 schedules. Disease control rate (percentage of patients with complete or partial response or stable disease) was 61.5 % and 69.2 % in the daily and weekly schedules, respectively. Median progression-free survival ranged from 5.1 months (95 % CI, 1.6-8.4 months) in the step 1 daily schedule to 9.0 months (95 % CI, 2.7-10.2 months) in the step 2 weekly schedule ( Table 7) .
Discussion
Based on preclinical and clinical evidence suggesting benefits for adding everolimus to cytotoxic chemotherapy, the present study was conducted to identify feasible everolimus doses given with carboplatin plus paclitaxel±bevacizumab in previously untreated advanced and metastatic NSCLC (at the time of trial design, carboplatin plus paclitaxel± bevacizumab was a standard regimen). Based on the probability of the end-of-cycle 1 DLT rate falling within the targeted toxicity interval, everolimus 5 mg/day and 30 mg/week were identified as the feasible everolimus doses. However, given that 74 % of patients experienced ≥1 DLT at any cycle, 44 % discontinued treatment due to AEs, and 56 % experienced ≥1 serious AE, this regimen may not be appropriate for long-term administration.
The model-derived end-of-cycle 1 DLT rate was similar across steps 1 and 2, whereas the DLT rate across all cycles was higher in step 2. Final data at study end showed that when given with carboplatin, paclitaxel, and bevacizumab, everolimus 5 mg/day (as opposed to 2.5 or 10 mg/day) maximized the chance of being within the targeted toxicity interval while reducing risk of excessive and unacceptable toxicity (59 % chance that end-of-cycle 1 DLT rate would be within the targeted toxicity interval and 14 % chance it would be within the excessive/unacceptable range). Based on these results, everolimus 5 mg/day was considered to be the feasible daily dose. Considering weekly dosing, final Table 4 Adverse events experienced during the core treatment phase (safety population)
Step 1 Step 2 AEs of any grade, grade 3/4 AEs, and serious AEs are listed by preferred term in order of decreasing incidence over all treatment arms AE adverse event, CP carboplatin and paclitaxel, CPB, carboplatin, paclitaxel, and bevacizumab data showed that everolimus 30 mg/week combined with carboplatin, paclitaxel, and bevacizumab was associated with a 29 % chance the end-of-cycle 1 DLT rate would be within the targeted toxicity interval and a 1 % chance it would be within the excessive/unacceptable toxicity interval. Although the final model showed that everolimus 50 mg/week provided the greatest chance the end-of-cycle 1 DLT rate was within the targeted toxicity interval (44 % vs 8 % for 20 mg/week and 29 % for 30 mg/week), the risk of excessive or unacceptable toxicity with 50 mg/week was considered unacceptable (27 %). Therefore, everolimus 30 mg/week was considered the feasible weekly dose. The observed carboplatin, paclitaxel, and bevacizumab RDIs suggest that everolimus 5 mg/day and 30 mg/week allow patients in both the daily and weekly schedules to achieve adequate drug exposure. Given the small sample size, it is not possible to conclude which schedule should be preferred. There were no unexpected safety signals observed when adding everolimus to carboplatin and paclitaxel±bevacizumab. All patients experienced ≥1 AE, and 90.4 % experienced ≥1 grade 3/4 abnormality, most commonly neutropenia. The overall incidence of grade 3/4 abnormalities was comparable across steps 1 and 2. Interestingly, the AE profile observed in this Table 5 Duration of exposure and relative dose intensity during the core treatment phase (safety population)
Step 1 Step 2 The log-transformed parameters were modeled by means of a power model of log-dose by treatment, regimen, and schedule. Samples with zero actual dose (ie, treatment interrupted or discontinued) were excluded.
AUC 0-last area under the concentration-time curve from time 0 to the last measurable concentration sampling time, AUC tau area under the concentration-time curve over the dosing interval, C max maximum blood concentration, CP carboplatin and paclitaxel, CPB carboplatin, paclitaxel, and bevacizumab a Beta=1 when the exposure change is exactly dose proportional study was not generally consistent with the known everolimus safety profile. Many AEs frequently associated with everolimus, including noninfectious pneumonitis, hypersensitivity, hyperglycemia, and increased creatinine, were reported infrequently, and while stomatitis, hypophosphatemia, lymphopenia, and dyslipidemic events were reported, they were also infrequent and mostly of grade 1/2 severity. No wound-healing complications were noted. Overall, the AEs observed were broadly consistent with the Eastern Cooperative Oncology Group 4,599 study of carboplatin plus paclitaxel± bevacizumab [17] , albeit with increased frequency and severity of reported AEs. This may be related to the overlapping toxicity profiles of carboplatin, paclitaxel, bevacizumab, and everolimus, which may limit the ability to combine these drugs. A dose-escalation study of everolimus monotherapy in patients with advanced solid tumors indicated everolimus 10 mg/day and 50 mg/week resulted in maximum inhibition of two downstream effectors of mTOR signaling, ribosomal protein S6 kinase 1 (S6K1) and eukaryotic initiation factor 4G (eIF-4G) [22] . Everolimus 5 mg/day demonstrated near complete inhibition of S6K1 phosphorylation (pS6) and partial inhibition of eIF-4G phosphorylation (peIF-4G), whereas pS6 and peIF-4G were almost completely blocked with everolimus 10 mg/day [22] . Similar inhibition was seen with weekly dosing, where pS6 inhibition was almost complete at 20 mg/week, but sustained peIF-4G inhibition was only apparent at doses ≥50 mg/week [22] . Thus, escalation beyond everolimus 10 mg/day and 50 mg/week may only risk additional toxicities without any further mTOR pathway inhibition. Subsequent dose-finding studies of everolimus monotherapy for advanced solid tumors [23] [24] [25] have shown everolimus 5-10 mg/day or 20-50 mg/week to be well tolerated with modest clinical activity. In the present study of everolimus in combination with carboplatin and paclitaxel±bevacizumab in advanced, metastatic NSCLC, it is notable that the feasible everolimus monotherapy dose (10 mg/day) [23] [24] [25] was not evaluated due to toxicity concerns. Similarly, although everolimus 50 mg/week was identified as the feasible monotherapy dose [22] , 30 mg/week was identified as the feasible dose in this study due to cumulative toxicity conferred by carboplatin and paclitaxel± bevacizumab. The identification of lower everolimus doses when given with other anticancer agents is consistent with findings of combination studies in NSCLC [15, 26, 27] and other solid tumors [28, 29] .
Pharmacokinetic evaluations in this study showed a trend indicating a greater than dose-proportional increase in everolimus exposure when co-administered with carboplatin and paclitaxel and a less than dose-proportional increase when administered with carboplatin, paclitaxel, and bevacizumab. However, the wide confidence intervals associated with the observed dose proportionality estimates preclude firm conclusions.
Due to the small sample size in this study, no valid efficacy conclusions related to adding everolimus 5 mg/day and 30 mg/week to carboplatin and paclitaxel±bevacizumab can be drawn. These doses and schedules resulted in a disease control rate of 61.5 %-69.2 % and a median progression-free survival of 5.1-9.0 months in this molecularly unselected population. More robust evaluation in specifically selected or molecularly defined populations would be necessary to investigate whether everolimus could improve the therapeutic index of carboplatin and paclitaxel±bevacizumab in these subsets. Table 7 Efficacy outcomes (full analysis set)
Step 2 In conclusion, based on the primary study endpoint of endof-cycle 1 DLT rate, the feasible everolimus doses given with carboplatin and paclitaxel±bevacizumab were 5 mg/day and 30 mg/week. These doses were not very well tolerated due to overlapping toxicities, with cytopenias, including neutropenia, the most common AEs. Based on the known efficacy of everolimus in pancreatic neuroendocrine tumors [30] , a prospective phase II study of everolimus plus carboplatin and paclitaxel as first-line therapy for stage IV large cell lung carcinoma with neuroendocrine differentiation is currently ongoing (ClinicalTrials.gov identifier NCT01317615).
